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Expression of parathyroid hormone-related protein (PTHrP) cor-
relates with prostate cancer skeletal progression; however, the
impact of prostate cancer-derived PTHrP on the microenviron-
ment and osteoblastic lesions in skeletal metastasis has not been
completely elucidated. In this study, PTHrP overexpressing pros-
tate cancer clones were stably established by transfection of full
length rat PTHrP cDNA. Expression and secretion of PTHrP
were verified by western blotting and IRMA assay. PTHrP over-
expressing prostate cancer cells had higher growth rates in vitro,
and generated larger tumors when inoculated subcutaneously into
athymic mice. The impact of tumor-derived PTHrP on bone was
investigated using a vossicle co-implant model. Histology revealed
increased bone mass adjacent to PTHrP overexpressing tumor
foci, with increased osteoblastogenesis, osteoclastogenesis and
angiogenesis. In vitro analysis demonstrated pro-osteoclastic and
pro-osteoblastic effects of PTHrP. PTHrP enhanced proliferation
of bone marrow stromal cells and early osteoblast differentiation.
PTHrP exerted a pro-angiogenic effect indirectly, as it increased
angiogenesis but only in the presence of bone marrow stromal
cells. These data suggest PTHrP plays a role in tumorigenesis in
prostate cancer, and that PTHrP is a key mediator for communi-
cation and interactions between prostate cancer and the bone
microenvironment. Prostate cancer-derived PTHrP is actively
involved in osteoblastic skeletal progression.
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Prostate cancer is a common malignant disease that characteris-
tically affects bones as it progresses. More than 65–75% of late
stage patients have skeletal metastases.1 The progression of pros-
tate cancer in bone results in pathological fractures, bone pain and
spinal cord compression. These complications severely lower
patients’ quality of life.2,3 Prostate cancer skeletal involvement is
a complicated process, in which bone provides a favorable me-
dium for tumor growth, resulting in alterations in bone remodeling
and development of cancer-associated bone lesions. Prostate can-
cer and the bone microenvironment communicate and interact
with each other throughout the progression of skeletal metastasis.
Clinical studies have shown that prostate cancer metastases are
often in the axial skeleton and long bone metaphyses, sites with
active remodeling.4,5 In vivo studies in animal models support the
hypothesis that prostate cancers prefer to localize at regions with
high bone turnover.6,7 Studies have shown that enhancing bone
turnover increased the localization of prostate cancer to the skele-
ton, whereas inhibiting bone resorption suppressed skeletal lesions
by prostate cancer cells.8–10 Prostate cancer cells may, like hema-
topoietic stem cells, adhere and localize at active remodeling sites
by a calcium sensing receptor-mediated mechanism, at least in
part, regulated by the action of parathyroid hormone-related pro-
tein (PTHrP).11–13
High expression of PTHrP correlates with skeletal metastasis
in numerous cancers including prostate cancer.14 Expression of
PTHrP in prostate cancer has been associated with increased
malignancy.15 It has been proposed that tumor-derived PTHrP
plays a critical role in skeletal metastasis by a vicious cycle, in
which PTHrP enhances bone remodeling and release of numer-
ous biological factors, providing a fertile environment for further
tumor growth.2 Tumor-derived PTHrP may also facilitate
skeletal progression by directly stimulating tumor cell prolifera-
tion, adhesion and survival using autocrine or paracrine
mechanisms.16–21
Tumor-derived PTHrP may be an important mediator of cancer-
induced skeletal lesions. PTHrP has some of the same biological
effects as PTH by binding to their common receptor, the PTHR1.
Both can have dual effects on bone remodeling. It has been well
characterized that PTH and PTHrP are potent stimulators of osteo-
clastogenesis by enhancing the production of RANK ligand
(RANKL) and MCP-1 by osteoblasts.22,23 RANKL induces differ-
entiation of osteoclast progenitor cells, and results in increased
bone resorption. However, PTH and PTHrP also have anabolic
effects on bone through mechanisms that are not yet well charac-
terized.24
Unlike other skeletal metastases which are typically osteolytic,
most prostate cancers result in osteoblastic skeletal lesions,3 char-
acterized as increased bone formation. Several osteoblastic fac-
tors, such as BMPs, TGF-b, FGFs, IGFs, PDGF, VEGF and endo-
thelins, are produced by prostate cancer cells. Most of these fac-
tors regulate osteoblast function by activating signaling pathways
involved in osteoblast proliferation and differentiation.25 VEGF
may exert an osteoblastic role indirectly by promoting angiogene-
sis.26 Recently, it has been reported that Wnt signaling may be
one of the switches that converts prostate cancer bone metastatic
activity from osteolytic to osteoblastic.27
In this study, it was hypothesized that prostate cancer-derived
PTHrP is an important factor that mediates interactions between
the bone marrow microenvironment and prostate cancer, which
further facilitates the establishment of skeletal metastases and
osteoblastic alterations.
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Material and methods
Cell lines and tissue culture
The ACE-1 canine prostate cancer cell line28 was maintained at
37C and 5% CO2 in RPMI 1640 containing 10% fetal bovine se-
rum (FBS) and 1% penicillin–streptomycin (Invitrogen Corp.,
Carlsbad, CA). Human aorta endothelial cells (HAEC) and human
bone marrow endothelial cells (HBME) were maintained in
DMEM medium containing 10% FBS and 1% penicillin–strepto-
mycin.
Reagents
LipofectAMINE Plus lipid based transfection reagent was
obtained from Invitrogen. PTHrP peptide (1–34) and PTHrP (7–
34) were obtained from Bachem California (Torrance, CA).
CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propane-
sulfonic acid) was from U.S. Biochemical Corp. (Cleveland, OH).
Rabbit anti-von Willebrand factor (vWF) antibody was acquired
from NeoMarkers (Fremont, CA). Anti-PTHrP rabbit antibody for
immunohistostaining was from EMD Biosciences (San Diego,
CA). Anti-PTHrP rabbit antibody for Western blot was from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-Ki67 was obtained
from Abcam (Cambridge, MA). Dexamethasone, mouse anti-tubu-
lin antibody and bovine serum albumin were obtained from Sigma
Aldrich (St. Louis, MO).
Transfection and selection
A full-length rat PTHrP cDNA (1–141) was cloned into expres-
sion vector pcDNA3 (Invitrogen).29 The pcDNA3.11 control vec-
tor was obtained from Invitrogen. All transfections were per-
formed with LipofectAMINE Plus reagents following manufac-
turer’s recommended protocols. After transfection, resistant
clones were selected with 800 lg/ml G418. The expression of tar-
get genes was screened by Western blot analysis. The secreted
PTHrP was analyzed using an IRMA system (Diagnostic Systems
Laboratories, Inc., Webster, Texas) according to manufacturer’s
direction.
Western blot analysis
Cells were washed in ice-cold 13 PBS, scraped, and pelleted
by centrifugation (500g, 5 min). The cell pellet was resuspended
and incubated for 15 min in 13 lysis buffer [20 mmol/l MOPS, 5
mmol/l MgCl2, 0.1 mmol/l ethylene-diamine-tetra-acetic acid
(EDTA), 200 mmol/l sucrose (pH 7.4), containing 1% CHAPS
and phosphatase and protease inhibitors]. Cell suspensions were
centrifuged at 13,000g for 10 min to remove nuclei and cell debris.
The protein concentration was determined by Bradford method.
Lysates containing equal amounts of protein (50 lg) were sepa-
rated by SDS-PAGE and transferred to polyvinylidene difluoride
membrane (Bio-Rad Laboratories, Hercules, CA). The membrane
was blocked with 5% nonfat milk in TBS-0.1% Tween 20. Blots
were incubated with primary antibodies for 2 hr at room tempera-
ture or overnight at 4C. Following washing in TBS-0.1% Tween
20, blots were incubated with horseradish peroxidase-labeled
secondary antibodies (1:10,000) for 1 hr at room temperature.
After washing, the signals were detected by standard enhanced
chemiluminescence.
Growth curve in vitro
Five thousand (5 3 103) cells were plated in each well of 24-
well plates in quadruplicate in the presence of serum at indicated
concentrations. The cells were fixed on the indicated days for sub-
sequent staining with crystal violet.30 DNA binding dye was solu-
bilized with 10% acetic acid. Relative cell numbers were meas-
ured by optical density at 595 nm.
Experimental animals
All experimental animal procedures were performed in compli-
ance with the institutional ethical requirements and were approved
by the University of Michigan Committee for the Use and Care of
Animals. Athymic mice (4–6 weeks) were purchased from Harlan,
(Indianapolis, IN). (i) Male athymic mice (5 animals per condition
in 2 separate experiments) were injected subcutaneously in each
flank with 5 3 104 tumor cells, which were suspended at 5 3 106
cells/ml in Hank’s buffered saline solution (Invitrogen). After 6
weeks, tumors were dissected and weighed. (ii) Bone implantation
was performed as previously described, with minor modifica-
tion.31 Briefly, vertebrae were isolated under sterile condition
from 8-day old mice. Soft tissue was dissected, and vertebrae were
sectioned into vertebral bodies (vossicles) with a scalpel blade.
Five thousand (5 3 103) prostate cancer cells were injected into
each vossicle. Male athymic mice were used as transplant recipi-
ents (5 animals per condition in 2 separate experiments). After an-
esthesia (i.p. injection of a mixture of ketamine [90 mg/kg] and
xylazine [5 mg/kg]), vossicles (4 per mouse) were implanted into
subcutaneous pouches. One centimeter incisions were made along
the backs of mice, pouches were made on either side of the inci-
sion with blunt dissection, and vossicles were implanted. After 6
weeks, vossicles were removed from transplant recipients, and
exposed to X-ray film (Wolverine X-Ray, Dearborn, MI) at 33,
32 kV, 45 sec in a microradiography X-ray machine (Faxitron,
Madison, WI) to compare bone density.
Histomorphometry and Immunohistochemistry
All samples were fixed with PBS-buffered 10% (v/v) formalde-
hyde for 24 hr. Bone samples were demineralized in 10% EDTA
(pH 7.4) for 4 weeks. Tissues were paraffin embedded, sectioned
and stained with either hematoxylin and eosin (H&E), Trichrome
stain for bone, TRAP staining for osteoclasts, or used for immuno-
histochemistry. For immunohistochemistry, tissue sections were
deparaffinized with xylene and rehydrated through a series of
graded ethanol (100, 95, 70, 50 and 30%), with a final wash in
water. Antigen retrieval was performed with 5 mg/ml pepsin in 5
mM HCl at 37C for 10–15 min. Standard indirect immunoperoxi-
dase procedures were used for immunohistochemistry using the
AEC system Cell and Tissue staining kit (R&D systems, Minneap-
olis, MN). Mayer’s hematoxylin (Sigma-Aldrich, Sigma, St.
Louis, MO) was used for counterstaining. The proliferation
marker Ki-67 index was determined by the average percentage of
tumor cells with nuclear staining in 5 different 4003 fields.
Microvessel density analysis
Microvessel density analysis (MVD) was performed as
described in the literature32 with modification. Tissue sections
were stained for vWF using immunohistochemistry. Four random
areas per tumor section were selected. Any single or cluster of en-
dothelial cells that was clearly separated from adjacent microves-
sels was considered as one countable microvessel. The average
vessel count (MVD) was determined for each specimen. For tissue
array, total numbers of vessels were used as MVD for each indi-
vidual section.
Colony formation assay
Bone marrow cells were isolated from long bones as previously
described.33 Briefly, bone marrow from the femoral, tibial and
humeral cavities was flushed using a-modified minimum essential
medium (a-MEM) with 20% serum and 10 nM dexamethasone.
CFU assays were performed as described34 with modification.
Bone marrow cells (5 3 106) were plated onto 6-well culture
plates in a-MEM with 20% serum, 10 nM dexamethasone, 50 lg/
ml ascorbic acid and 10 mM b-glycerophosphate containing either
vehicle or indicated concentrations of PTHrP (1–34). Vehicle or
PTHrP (1–100 nM) was added to cultures every other day. After
10 days, colonies formed were fixed and stained for alkaline phos-
phatase activity (ALP) to detect positive colonies (CFU-ALP), fol-
lowed by crystal violet stain for total colonies (CFU-F). The stain-
ing of ALP activity in situ was performed with a histochemical kit
from Sigma following manufacturer’s procedure.
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In vitro osteoclastogenesis
Bone marrow cells (5 3 106) were plated onto 6-well culture
plates in a-MEM with 20% serum, 10 nM dexamethasone, 50 lg/
ml ascorbic acid and 10 mM b-glycerophosphate. After treatment
with vehicle, PTHrP (1–100 nM), or conditioned medium every
other day for 10 days, cells were fixed, stained for TRAP positive
cells (per protocol from the Luckeucyte Acid-phosphatase staining
kit (Sigma)), and conterstained with Mayer’s hematoxylin. Osteo-
clast-like cells in each well were scored by counting the number
of TRAP-positive cells containing 3 or more nuclei.
FIGURE 1 – Characterization of PTHrP overexpressing ACE-1 cells. (a) Full length rat PTHrP cDNA was transfected into the ACE-1 canine
prostate cancer cell line using LipofectAMINE Plus. Stable clones were selected with G418. Expression levels of PTHrP in cell lysates were
screened with western blot; (b) secretion of PTHrP in medium by prostate cancer stable clones was verified with IRMA; (c,d) comparison of in
vitro proliferation assay of vector control (PCa-Vector) and PTHrP overexpressing ACE-1 cells (PCa-PTHrP) in the presence of 1% (c) and 0%
serum (d). Cell numbers at indicated days were measured by crystal violet staining and shown as optical density at 595 nm (**p < 0.01, PCa-
PTHrP vs. PCa-Vector, n5 4); (e) representative images of subcutaneous tumors. (f) Subcutaneous growth of PCa-PTHrP tumor and vector con-
trol after 6 weeks (**p < 0.01, PCa-PTHrP vs. PCa-Vector, n 5 5); (g) vWF as a marker of vascularity was determined by immunostaining in
sections of subcutaneous tumors. Sections were counterstained with Mayer’s hematoxylin. (red, vWF; blue, nuclei; magnification 3200).
(h) Proliferation rate was measured with immunohistostaining for Ki-67 (*p < 0.05, PCa-PTHrP vs. PCa-Vector, n5 8 and 7, respectively).
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In vitro osteoblastogenesis
Freshly isolated bone marrow cells were maintained in a-MEM
with 20% serum, and 10 nM dexamethasone at 37C in an atmos-
phere of 100% humidity and 5% carbon dioxide. Medium was
refreshed after 1 week. The adherent cell layers (bone marrow
stromal cells, BMSC) were harvested when confluent. One hun-
dred thousand (1 3 105) cells were seeded in each well of a 12-
well plate. The medium was refreshed every other day with a-
MEM containing 20% serum, and 10 nM dexamethasone, 50 lg/ml
ascorbic acid and 10 mM b-glycerophosphate, plus either vehicle
or PTHrP (10 nM). One week later, staining for ALP activity was
performed as described earlier. The intensity of ALP staining was
quantified from scanned plates using a UMAX scanner (Techville,
Dallas, TX) and Image pro plus software (Media Cybernetics, Be-
thesda, MD). For co-culture assays, 2,000 (23 103) prostate cancer
cells were coplated with 1 3 105 BMSC into 12-well plates in a-
MEM with 20% serum, and 10 nM dexamethasone, 50 lg/ml ascor-
bic acid and 10 mM b-glycerophosphate. Medium was refreshed
FIGURE 2 – Osteoblastic lesions in vossicle implants with PTHrP overexpressing tumors. (a) Representative radiography of vossicles; (b)
quantification of bone area in vossicle implants from trichrome-stained sections (***p < 0.001, PCa-PTHrP vs. PCa-Vector, n 5 19 and 20,
respectively); (c) representative trichrome staining of vossicles with PCa-PTHrP and PCa-Vector (magnification 320). PTHrP overexpressing
tumors resulted in greater bone area (stained in blue) compared to vector controls. (d) Quantification of tumor area in vossicle implants from
HE-stained sections (*p < 0.05, PCa-PTHrP vs. PCa-Vector, n 5 19 and 20, respectively; (e) bone area/tumor area (**p < 0.01, PCa-PTHrP vs.
PCa-Vector, n5 19 and 20, respectively).
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every other day. After 1 week, ALP staining and quantification
were performed as described earlier. The arbitrary relative units
were obtained by comparing with vehicle control.
Endothelial sprout network formation assay
Growth factor-reduced Matrigel (BD Biosciences, San Jose, CA)
was placed in 8-well chamber slides, and incubated at 37C for 30
min to allow the Matrigel to polymerize.35 Six thousand (6 3 103)
HAEC were added to the top of the Matrigel in each well. The
chambers were then incubated at 37C for 24 hr. After incubation,
the slides were fixed and stained with Hema 3 STAT PACK (Proto-
col, Kalamazoo, MI). The slides were examined, and the sprouts
were counted under a light microscope. For co-culture assays, equal
numbers of BMSC and endothelial cells were included.
RNA isolation, reverse transcription and real-time PCR
Total RNAs were prepared using Trizol reagent (Invitrogen).
Total RNA (1 lg) was reverse transcribed in a 20 ll reaction vol-
ume containing random hexamers with a reverse transcription
assay system (Applied Biosystems, Foster City, CA). Reverse
transcription was performed at 25C for 10 min, 48C for 30 min
and 95C for 5 min. Real-time PCR was performed using the ABI
PRISM 7700 with FAM-labeled probe assay system (Applied
Biosystems, Foster City, CA). GAPDH was used as an internal
control.
Statistical analysis
Student’s t-test for independent analysis was applied to evalu-
ate differences using the GraphPad Instat software program
FIGURE 3 – Alterations in the microenvironment with tumor-derived PTHrP. (a,b) Representative H&E-stained sections (T, tumor; OB, osteo-
blasts; OC, osteoclasts; BV, blood vessel; magnification 3200); (c) quantitative numbers of osteoclasts per mm bone surface (***p < 0.001,
PCa-PTHrP vs. PCa-Vector, n5 19 and 15, respectively); (d) quantitative data of osteoclasts covering bone surfaces (***p < 0.001, PCa-PTHrP
vs. PCa-Vector, n 5 19 and 15, respectively); (e–h) localization of tumor, bone, and vascularity. Consecutive sections of osteoblastic lesions by
PCa-PTHrP were stained with H&E (e) and trichrome (f; bone: blue), or immunostained for PTHrP (g; PTHrP: red) or vWF (h; vWF: red) (T, tu-
mor) (magnification 3200). (i,j) Consecutive sections of vossicle implant with PCa-vector immunostained for PTHrP (i) or vWF (j); (k) MVD
in tumor area was measured using vWF staining. (***p < 0.001; PCa-PTHrP vs. PCa-Vector, n5 18 and 20, respectively).
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(GraphPad Software, San Diego, CA). The value p < 0.05 was
considered statistically significant. All assays were repeated at
least twice with similar results.
Results
Over expression of PTHrP enhanced prostate
cancer tumorigenesis
A full-length rat PTHrP (1–141) cDNA was transfected into
ACE-1 prostate cancer cells. PTHrP overexpressing clones stably
selected in G418 were screened using Western blotting (Fig. 1a),
and the secreted PTHrP levels of selected clones were measured
with IRMA (Fig. 1b). The secreted PTHrP concentrations in
vector controls were 2.27–13.21 pg/ml/48 hr, while the PTHrP-
overexpressing clones secreted 546–3,543 pg/ml/48 hr. Unless
otherwise indicated, PTHrP-overexpressing clone 5 was used for
the majority of experiments.
To measure cell numbers over time, cells were cultured for 6
days in medium that contained either 0 or 1% serum. Cell numbers
at indicated days were measured by crystal violet staining and are
FIGURE 4 – PTHrP induced osteoblastogenesis. (a,b) CFU assay. Bone marrow cells (5 3 106) were plated onto 6-well culture plates and
were treated with vehicle or PTHrP(1–34) (1–100 nM). CFU-ALP and CFU-F were measured at day 7 (**p < 0.01, PTHrP vs. vehicle control,
n 5 4 each); (c) proliferation of bone marrow stromal cells in response to PTHrP (10 nM), as measured with crystal violet staining (*p < 0.05,
**p < 0.01, PTHrP vs. vehicle control, n 5 4); (d) comparative ALP staining in vitro was measured as described in materials and methods
(***p < 0.001, n 5 3); (e) representative ALP staining of BMSC culture with treatment of vehicle or PTHrP (10 nM), or co-cultured with PCa-
PTHrP or PCa-Vector for 7 days; (f) comparison of pro-osteoblastogenic ability in different clones of PTHrP overexpressing ACE-1 cells with
vector control using ALP staining. P1, P4 and P5 secreted low, medium and high levels of PTHrP, respectively (**p < 0.01, ***p < 0.001, vs.
vector control, n5 6). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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shown as optical density at 595 nm. Prostate cancer cells with
PTHrP overexpression had increased growth rate over time in the
presence of 1% serum (Fig. 1c). Without serum, both PTHrP over-
expressing prostate cancer cells and vector controls had a similar
growth curve (Fig. 1d).
To investigate the potential effect of PTHrP on tumorigenicity,
male athymic mice were injected subcutaneously in each flank
with 5 3 104 tumor cells. Subcutaneous tumors were dissected
and weighed after 6 weeks. As shown in Figures 1e and 1f, PTHrP
overexpressing cells resulted in larger tumors than vector control
(0.34 6 0.16 g vs. 0.08 6 0.04 g, p < 0.01). Histology demon-
strated no qualitative difference in vascularization, as determined
by vWF immunohistostaining, in PTHrP-overexpressing tumors and
vector control tumors (Fig. 1g). Ki-67 immunohistostaining of
PTHrP-overexpressing tumors demonstrated PTHrP increased cell
proliferation (Fig. 1h; PTHrP 11%6 1.2% vs. control 6.9%6 0.8%,
p< 0.05).
Impact of prostate cancer-derived PTHrP on bone
To investigate the effects of tumor-derived PTHrP on bone dur-
ing skeletal progression, prostate cancer clones with PTHrP over-
expression or vector controls were co-implanted with donor verte-
brae. After 6 weeks, implants were removed from transplant recip-
ients and radiographed. PTHrP-overexpressing clones resulted in
radiographically denser bone implants (Fig. 2a). Trichrome stain-
ing of implant sections further demonstrated increased total bone
area (0.36 6 0.22 mm2 vs. 0.12 6 0.06 mm2, p < 0.001) (Figs. 2b
and 2c) in PTHrP-overexpressing implants. PTHrP-overexpressing
implants also had larger tumors (Fig. 2d), while the index of bone
area/tumor area was still significantly greater than the vector con-
trol group (Fig. 2e).
Alteration of microenvironment by PTHrP overexpressing
prostate cancer cells
The morphology of tumors in vossicles with H&E staining is
shown in Figure 3. Compared to the vector control group, PTHrP
overexpression resulted in significantly more osteoclasts (3.32 6
1.34 mm vs. 0.78 6 0.64 mm, p < 0.001) (Fig. 3c). The PTHrP
group also had more osteoclast-covered bone surface peri-
meter than vector control (7.73% 6 3.25% vs. 2.23% 6 1.90%,
p < 0.001) (Fig. 3d). PTHrP immunohistochemistry showed that
PTHrP-overexpressing tumor microfoci expressed high levels of
PTHrP adjacent to osteoblastic lesions (Fig. 3g) and large islands
of bone, as shown in H&E and Trichome stain, formed around
microtumor foci (Figs. 3e and 3f). A layer of blood vessels (as
detected by vWF staining) was frequently seen around PTHrP-
expressing tumors (Fig. 3h). In H&E staining, mesenchymal cells
surrounded tumors and filled the space between tumors and bones
(Figs. 3b and 3e). Blood vessels localized at the interface between
tumor and mesenchymal cells. The microvessel density (MVD) in
PTHrP overexpressing implants was significantly greater com-
pared to the vector controls (18.5 6 2.69 vs. 7.16 0.75) (Fig. 3k).
PTHrP over-expressing prostate cancer
enhanced osteoblastogenesis
Bone marrow stromal cell populations contain osteoblast pre-
cursors. To determine the effect of PTHrP on osteoblast commit-
ment, bone marrow cells from long bones (tibia and femur) were
FIGURE 5 – PTHrP induced osteoclastogenesis. (a) Representative data of in vitro osteoclastogenesis by PTHrP from whole bone marrow
(magnification 3100). Bone marrow cells (5 3 106) were plated into 6-well culture plates and were treated with vehicle or PTHrP (1–100 nM)
every other day for 10 days. TRAP staining was performed. Osteoclasts are indicated with arrows; (b) the numbers of osteoclasts were counted as
TRAP-positive cells with 3 or more nuclei (*p < 0.05, **p < 0.01, PTHrP vs. vehicle, n 5 3); (c) average numbers of nuclei per osteoclast. (*p <
0.05, **p < 0.01, PTHrP vs. vehicle, n 5 3); (d) comparison of pro-osteoclastogenic ability of different clones of PTHrP overexpressing ACE-1
cells with vector control using TRAP staining. P1, P4 and P5 secreted low, medium and high level of PTHrP, respectively (*p < 0.05, **p < 0.01,
***p < 0.001, vs. vector control, n5 3). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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plated and treated with various concentrations of PTHrP (1–34) or
vehicle every other day for 10 days, and ALP-positive and total
colony forming units were compared. The number of CFU-ALP
were increased by PTHrP at concentrations of 10–100 nM, while
the relative CFU-F were unchanged at these concentrations (Figs.
4a and 4b). The pro-proliferative effect of PTHrP on early stage
osteoblasts has been reported.36 Consistently, PTHrP treatment
enhanced the numbers of BMSC during a 6-day period (Fig. 4c).
To evaluate osteoblastogenesis of tumor-derived PTHrP, BMSC
were co-cultured with either vector control or PTHrP-overexpress-
ing prostate cancer cells. PTHrP-overexpressing prostate cancer
caused increased ALP staining compared to vector control (4.5 6
0.2 vs. 2.6 6 0.1 arbitrary units, PTHrP overexpressing vs. vector
control, p < 0.001) (Figs. 4d and 4e). These results were com-
pared to the effects seen with treatment of BMSC cultures with ve-
hicle or 10 nM PTHrP (1–34) (1.0 6 0.1 vs. 3.6 6 0.6 arbitrary
units, p < 0.001). All the tested PTHrP-overexpressing clones
induced increased ALP staining compared to the vector control
(Fig. 4f).
PTHrP enhanced osteoclastogenesis ex vivo
The effect of PTHrP on osteoclastogenesis was determined by
treating whole bone marrow in culture every other day for 10
days, followed by TRAP staining and enumeration of multi-
nucleated TRAP positive cells. The number of TRAP-positive,
multinucleated osteoclasts was increased with PTHrP treatment in
a dose-dependent manner (Figs. 5a and 5b). PTHrP also enhanced
the numbers of nuclei per TRAP-positive cell (Fig. 5c). All the
tested PTHrP-overexpressing clones induced increased osteoclas-
togenesis compared to the vector control (Fig. 5d).
Increased microvessels in human prostate cancer metastasis
Immunostaining of vWF in a human prostate cancer tissue array
demonstrated that skeletal metastases had increased microvessel
density (MVD), compared to that of normal prostate and primary
prostate cancer (Figs. 6a and 6b). Immunolocalization in human
prostate cancer autopsy revealed that vWF positivity was adjacent
to the area of PTHrP immunostaining in prostate cancer skeletal
metastases (Fig. 6c).
PTHrP enhanced angiogenesis indirectly via BMSCs
Though it was reported that endothelial cells have low levels of
PTHR1 detected by reverse transcription and PCR, it has not been
reported to be detected using other approaches.37 Endothelial cells
also lack PTHrP binding activity as measured with 125I-labeled
PTHrP.38 Using highly sensitive and specific real-time PCR,
PTHR1 expression in HAEC and HBME endothelial cells was
tested in this study using human osteosarcoma SaOS cell line as
the positive control. The PTHR1 was not detectable in the endo-
thelial cell lines (Fig. 7a).
The histology of PTHrP overexpressing prostate cancer-induced
osteoblastic lesions identified regions of angiogenesis localized at
the interface of PTHrP-expressing tumor and mesenchymal cells
(Fig. 3h). These findings suggested that PTHrP may act indirectly
to promote angiogenesis. To test this hypothesis, in vitro angio-
genesis assays were evaluated using human aortic endothelial
cells. Endothelial cells were treated with PTHrP in the presence or
absence of BMSC. Neither PTHrP nor BMSC alone caused the
formation of vascular sprouts (Figs. 7b–7d). In contrast, PTHrP in
the presence of BMSC significantly enhanced vascular sprouts. To
evaluate the pro-angiogenic effect of tumor-derived PTHrP, endo-
thelial cells were co-cultured with either vector control or PTHrP
overexpressing prostate cancer cells in the presence or absence of
BMSC. Compared to no tumor cells, vector control tumor cells
alone increased vascular sprouts in either the presence or absence
of BMSC, suggesting angiogenic factors are produced by prostate
cancer cells. In the absence of bone marrow cells, PTHrP overex-
pression did not alter vascular sprouts as compared to vector con-
trols. In the presence of BMSC, PTHrP-overexpressing cells
resulted in a much higher level of vascular sprouting. Since cocul-
ture of endothelial cells with BMSC did not result in formation of
vascular sprouting (Figs. 7b and 7d), this suggested that BMSC
are mediators of vascular sprouting induced by PTHrP overex-
pressing tumor cells.
To identify potential factors induced by PTHrP in BMSC, sev-
eral angiogenic cytokines were measured using real-time PCR
(Figs. 8a–8d). The production of IL-6 and CXCL1 by BMSC were
rapidly and significantly induced by PTHrP. At 1 hr, the mRNA
level of IL-6 increased more than 180-fold and CXCL1 increased
more than 60-fold. PTHrP also induced a moderate increase of
MCP-1 (6.7-fold at 4 hr) and a less but still significant increase in
VEGF (1.3-fold at 1 hr). To confirm that the increase in vascular
sprouting by PTHrP-overexpressing tumors was due to PTHrP,
FIGURE 6 – MVD in human autopsy specimens. (a) Representative
images of vWF staining in human PCa tissue array. Blood vessels are
indicated with arrows; (b) total number of blood vessels were counted
per section of tissue array (*p < 0.05, **p < 0.01); (c) immunohistos-
taining for PTHrP and vWF in human prostate cancer skeletal meta-
static lesions. Blood vessels are indicated with arrows.
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PTHrP (7–34) was used as an antagonist to suppress PTHrP sig-
naling. PTHrP(7–34) prevents PTHrP binding to its receptor and
blocks its signaling.39 Two micromolar PTHrP(7–34) was chosen
to give sufficient and sustained suppression for PTHrP signaling
during the in vitro vascular sprouting assay. PTHrP(7–34) was
able to suppress the increase in vascular sprouting induced by
PTHrP-overexpressing tumor cells (Fig. 8e).
Discussion
Expression of PTHrP correlates with the progression of skeletal
metastasis in prostate cancer patients.40 Substantial in vivo studies
support that PTHrP expression regulates tumor progression.15,41–43
One possible mechanism for this effect is that PTHrP enhances
bone turnover and releases bioactive factors that facilitate tumor
localization and growth in bone.2,6–11 In this study, the effects of
PTHrP on tumorigenesis and cancer-induced bone lesions were
investigated with a mouse model using canine prostate cancer
cells that were stably transfected to overexpress full length
PTHrP.
ACE-1 is a canine prostate cancer cell line that is particularly
useful in these studies because of its ability to induce osteoblastic
lesions similar to those often seen in human prostate cancer.28
Radiographs of tumors generated by these cells demonstrate a mixed
osteoblastic/osteolytic lesion. The ACE-1 cells express low levels of
endogenous PTHrP, and no detectable PTHR1 (supplementary
FIGURE 7 – PTHrP induced angiogenesis with bone marrow stromal cells. (a) Detection of PTHR1 in endothelial cells with reverse transcrip-
tion and real-time PCR (ND, not detectable); (b) representative data of in vitro angiogenesis analysis in response to vehicle or PTHrP (10 nM)
treatment in the presence (1BMSC) or absence of bone marrow stromal cells(2BMSC); (c) representative data of in vitro angiogenesis analysis
in the presence (1BMSC) or absence of bone marrow stromal cells(-BMSC) when co-cultured with prostate cancer cells (magnification 340);
(d) quantitative data of in vitro angiogenesis analysis (*p < 0.05, **p < 0.01, n5 4–6).
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data). ACE-1 cells express a number of cytokines, such as VEGF,
FGF-2 and PDGF-BB.44 Transfection of full length rat PTHrP
DNA resulted in upregulation of PTHrP levels. ACE-1 cells with
high levels of PTHrP demonstrated increased tumorigenicity after
subcutaneous inoculation into athymic mice, as determined by
increased tumor weight in PTHrP transfectants vs. vector controls.
Consistently, ACE-1 cells with increased PTHrP expression grew
more rapidly in vitro. This could be associated with the antiapop-
totic activity of the nuclear localization sequence (amino-acid 87–
107) that we have previously described.29
A typical osteoblastic histological pattern was observed in ver-
tebrae implants with PTHrP-overexpressing tumors, in which new
bone was formed around microtumor foci, with increased adjacent
osteoblasts and osteoclasts. Increased numbers of osteoclasts in
implants with PTHrP-overexpressing tumors suggested increased
bone turnover caused by PTHrP. Mesenchymal cells surrounded
tumors and filled the space between tumors and bones. Interest-
ingly, a layer of blood vessels (as detected by vWF staining) was
frequently seen at the interface between tumor and mesenchymal
cells. These data suggest that tumor-derived PTHrP is actively
involved in the processes of osteoblastogenesis, osteoclastogenesis
and angiogenesis, which would imply that PTHrP is an important
factor responsible for pathological alterations of prostate cancer-
induced bone lesions.
Osteoblasts and osteoclasts are 2 major cell mediators of bone
remodeling. PTH/PTHrP supports osteoclastogenesis by upregu-
lating RANKL and MCP-1 in osteoblasts.22,23 Consistent in this
study, PTHrP enhanced osteoclast formation in vitro from bone
marrow cells in a concentration-dependent manner, correlating
with the in vivo results showing increased osteoclastogenesis with
increased PTHrP expression.
Prostate cancer-derived PTHrP is also a stimulator of osteoblas-
togenesis. In this study, BMSC in culture exhibited increased pro-
liferation when treated with PTHrP as compared to controls.
BMSC are precursors of several cell types including osteoblasts.45
Previous studies have shown that cyclin D1 is a key target of
PTHrP that mediates PTHrP-induced proliferation in early osteo-
blastic cells.36 When co-cultured with BMSC, PTHrP-overex-
FIGURE 8 – Bone marrow stromal cells were challenged with 10 nM PTHrP. (a–d) The mRNA levels of pro-angiogenic factors, IL-6,
CXCL1, MCP-1 and VEGF were measured using reverse transcription and real-time PCR (**p < 0.01, ***p < 0.001, PTHrP vs. vehicle, n 5
4); (e) HAEC in vitro angiogenesis analysis when co-cultured with prostate cancer cells and BMSC. PTHrP(7–34) (2 lM) suppressed PTHrP-
overexpressing PCa induced increase in vascular sprouting (*p < 0.05, n5 4).
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pressing prostate cancer cells stimulated ALP staining, suggesting
development of early osteoblastic cells. The in vitro proliferation
and osteoblast commitment assays supported the hypothesis that
PTHrP enhanced osteoblastogenesis by stimulating osteoblast
progenitor cell proliferation and by inducing early osteoblast
differentiation.
The successful establishment of metastasis relies on vasculari-
zation.46 New blood vessels are initially formed through the as-
sembly or sprouting of endothelial cells. The recruitment of sup-
porting pericytes and vascular smooth muscle cells ensures the
formation of a mature and stable vascular network.47 Within the
vasculature, endothelial cells produce PTHrP, while the PTH/
PTHrP receptor is reported to be located in pericytes and smooth
muscle cells.48 PTHrP produced by endothelial cells acts on
smooth muscle cells and may be of importance for the growth and
development of new vasculature.38 Interestingly, there are contra-
dictory reports about the effects of PTHrP on angiogenesis.49–52
An inhibitory effect on angiogenesis was first reported in an in
vivo model with the chick chorioallantoic membrane.49 PTHrP
gene delivery by adenovirus also inhibited angiogenesis and
growth of subcutaneous prostate tumors.49 Some reports have sug-
gested that PTHrP may inhibit angiogenesis by suppressing endo-
thelial migration in a protein kinase A-dependent manner.49 In
fetal skin of PTHrP or PTHR1 knockout mice, increases in the
length, diameter and density of capillaries were observed.50 In
contrast, rat pituitary malignant tumor cells, mGH3, which over-
expressed PTHrP, exhibited hypervascularization in xenografts
in vivo.51 Co-incubation with antisense PTHrP oligonucleotide
(10 lM), but not sense or mismatched PTHrP oligonucleotide,
suppressed mGH3-induced hypervascularization in diffusion
chambers.51 In a breast adenocarcinoma cell line (MDA-231),
PTHrP enhanced the production of connective tissue growth factor
(CTGF/CCN2), a factor that regulates endothelial proliferation
and migration, by autocrine or paracrine mechanisms.52 Since
PTHR1 is absent on endothelial cells, contradictory observations
may result from the difference in environment where different
PTHrP targeted cells exist.
This study showed that there was no significant difference in
density of vascularity between subcutaneous PTHrP-overexpress-
ing tumors and vector control tumors. However, increased angio-
genesis was observed in vossicles co-implanted with PTHrP-over-
expressing prostate cancer cells compared to vossicles co-
implanted with vector control, indicating that the pro-angiogenic
effect of PTHrP may require the unique bone microenvironment.
Noticeably, an increase in angiogenesis was found at the interface
of PTHrP overexpressing prostate cancer microfoci and mesenchy-
mal cells in vossicle implants. Thus, it is likely that tumor-derived
PTHrP may exert its proangiogenic effect indirectly via BMSC.
To test this, an in vitro assay was performed to examine
involvement of BMSCs in the pro-angiogenic effect of PTHrP.
The results showed that endothelial cells barely formed vascular
sprouts, in the presence of either PTHrP or BMSC. In the presence
of both PTHrP and BMSC, a significant increase in endothelial
cell-mediated angiogenesis was observed. These data support the
hypothesis that PTHrP acts as a pro-angiogenic factor via BMSCs.
Co-culture of endothelial cells with either vector control, or
PTHrP-overexpressing prostate cancer cells resulted in similar
levels of angiogenesis. In contrast, in the presence of BMSC,
PTHrP overexpressing transfectants caused significantly higher
angiogenesis than vector control. The data support that tumor-
derived PTHrP enhances angiogenesis via BMSC. Upon examina-
tion, the induction of several angiogenic factors including IL-6,
CXCL1, MCP-1 and VEGF from BMSC with PTHrP treatment
was found. Suppression of PTHrP overexpressing cancer cell-
induced vascular sprouting by PTHrP (7–34) supported PTHrP as
the key mediator. Using human clinical autopsy specimens, this
study also demonstrated prostate cancer skeletal metastases have
abundant vasculature compared to primary tumors. In human au-
topsy specimens, microvessels aligned along the surface of PTHrP
expressing microfoci. The data suggest prostate cancer-derived
PTHrP is a pro-angiogenic agent in skeletal metastasis by media-
ting the interactions between tumor and bone microenvironment.
Expression of PTHrP has been identified in many cancers, such
as prostate, breast, lung and others. Breast cancer-derived PTHrP
is an important factor associated with osteolytic lesions via
enhancing osteoclastogenesis.1–3 Unlike breast cancer, most pros-
tate cancers result in osteoblastic skeletal lesions.3 Prostate cancer
produces several osteoblastic factors, such as BMPs, TGF-b,
FGFs, IGFs, PDGF, VEGF and endothelins.25 This study demon-
strated that prostate cancer-derived PTHrP enhances both osteo-
clastogenesis and osteoblastogenesis. PTHrP, therefore, may
prime bone remodeling and mediate prostate cancer-induced
osteoblastic lesions. This study also provides evidence that PTHrP
is a mediator of tumor-associated angiogenesis. PTHrP exerted its
pro-angiogenic effect via BMSC by stimulating the production of
a number of angiogenic factors in these cells. Since angiogenesis
not only facilitates the establishment of metastasis, but is also an
important early step for bone formation,26,53 PTHrP is a key medi-
ator of prostate cancer skeletal progression. Targeting factors,
such as PTHrP, that mediate prostate cancer-bone microenviron-
ment interactions will be a promising strategy for therapy and pre-
vention of prostate cancer skeletal progression.
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